Abstract

BackgroundCauses of osteoporosis in patients with connective tissue diseases (CTD) are more complex than in patients with postmenopausal osteoporosis (PO). None of the studies published so far examined the safety...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
SAT0281 Comparison of the Efficacy and Safety of Zoledronic Acid Taken Once a Year in the Treatment of Postmenopausal and Glicocorticosteroid-Inducted Osteoporosis in the Course of Connective Tissue Disease – 5 Year Observation
M Wislowska ... B Jaszczyk
Annals of the Rheumatic Diseases | VOL. 74
M Wislowska, et. al.M Wislowska ... B Jaszczyk
01 Jun 2015
FRI0149 Serum cytokines and autoantibodies profile in rheumatoid arthritis and connective tissue diseases ? relationship to microvascular capillaroscopic abnormalities
A Kuryliszyn-Moskal ... S Sierakowski
-
A Kuryliszyn-Moskal, et. al.A Kuryliszyn-Moskal ... S Sierakowski
01 Jun 2001
Osteonecrosis of the jaw (ONJ) in renal cell cancer patients after treatment including zoledronic acid or denosumab
Vittorio Fusco ... Alberto Bedogni
Supportive Care in Cancer | VOL. 22
Vittorio Fusco, et. al.Vittorio Fusco ... Alberto Bedogni
26 Feb 2014
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis
Christina Bucci‐Rechtweg ... Aimee Readie
Journal of Bone and Mineral Research | VOL. 26
Christina Bucci‐Rechtweg, et. al.Christina Bucci‐Rechtweg ... Aimee Readie
02 Sep 2010
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers